ES2298130T3 - Uso de triacetiluridina para el tratamiento de trastornos mitocondriales. - Google Patents

Uso de triacetiluridina para el tratamiento de trastornos mitocondriales. Download PDF

Info

Publication number
ES2298130T3
ES2298130T3 ES00910321T ES00910321T ES2298130T3 ES 2298130 T3 ES2298130 T3 ES 2298130T3 ES 00910321 T ES00910321 T ES 00910321T ES 00910321 T ES00910321 T ES 00910321T ES 2298130 T3 ES2298130 T3 ES 2298130T3
Authority
ES
Spain
Prior art keywords
syndrome
mitochondrial
deficiency
worsening
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00910321T
Other languages
English (en)
Spanish (es)
Inventor
Robert K. Naviaux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2298130T3 publication Critical patent/ES2298130T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
ES00910321T 1999-02-23 2000-02-23 Uso de triacetiluridina para el tratamiento de trastornos mitocondriales. Expired - Lifetime ES2298130T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12158899P 1999-02-23 1999-02-23
US121588P 1999-02-23

Publications (1)

Publication Number Publication Date
ES2298130T3 true ES2298130T3 (es) 2008-05-16

Family

ID=22397641

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00910321T Expired - Lifetime ES2298130T3 (es) 1999-02-23 2000-02-23 Uso de triacetiluridina para el tratamiento de trastornos mitocondriales.

Country Status (20)

Country Link
US (2) US7638501B1 (enExample)
EP (2) EP1808177B1 (enExample)
JP (1) JP4776780B2 (enExample)
KR (2) KR100758712B1 (enExample)
CN (2) CN1191835C (enExample)
AT (1) ATE381935T1 (enExample)
AU (1) AU776437B2 (enExample)
BR (1) BR0008447A (enExample)
CA (1) CA2362925C (enExample)
DE (1) DE60037578T2 (enExample)
DK (1) DK1171137T3 (enExample)
ES (1) ES2298130T3 (enExample)
HU (1) HU230191B1 (enExample)
IL (3) IL144964A0 (enExample)
MX (1) MXPA01008549A (enExample)
NZ (1) NZ513926A (enExample)
PT (1) PT1171137E (enExample)
RU (2) RU2268732C2 (enExample)
WO (1) WO2000050043A1 (enExample)
ZA (1) ZA200107727B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
CA2339008C (en) * 1998-07-31 2009-12-15 Massachusetts Institute Of Technology Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
ES2298130T3 (es) 1999-02-23 2008-05-16 The Regents Of The University Of California Uso de triacetiluridina para el tratamiento de trastornos mitocondriales.
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
DE10110355A1 (de) * 2001-03-03 2002-09-12 Ulrich Walker Bekämpfung von Nebenwirkungen
CA2444148A1 (en) * 2001-04-11 2002-10-24 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
EP1395681B1 (en) * 2001-05-29 2006-07-26 The University of British Columbia Pharmacological applications of mitochondrial dna assays
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
JP2006515891A (ja) * 2003-01-17 2006-06-08 シーブイ・セラピューティクス・インコーポレイテッド 循環器疾患の処置に有効な置換ヘテロ環化合物
MX2007015006A (es) 2005-06-01 2008-03-18 Edison Pharmaceuticals Inc Sustancias terapeuticas activas redox para el tratamiento de enfermedades mitocondriales y otras condiciones o modulacion de biomarcadores de energia.
ES2823728T3 (es) * 2005-09-15 2021-05-10 Ptc Therapeutics Inc Variantes de cola de agentes terapéuticos con actividad redox para el tratamiento de enfermedades mitocondriales y otras afecciones y la modulación de biomarcadores de energía
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
US8748405B2 (en) 2007-01-26 2014-06-10 City Of Hope Methods and compositions for the treatment of cancer or other diseases
BRPI0817387A2 (pt) 2007-11-02 2015-09-08 Massachusetts Inst Technology métodos de conformidade de suplementação dietária de uridina e uso dos mesmos
CN101612110B (zh) * 2008-06-23 2012-07-25 欣凯医药化工中间体（上海）有限公司 三乙酰尿苷缓释制剂及其制备方法
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
RU2400221C2 (ru) * 2008-11-11 2010-09-27 ФГУ "Московский НИИ педиатрии и детской хирургии Росмедтехнологий" Способ лечения врожденных структурных миопатий и врожденных мышечных дистрофий путем коррекции вторичных митохондриальных изменений
ES2640485T3 (es) * 2011-08-12 2017-11-03 Universitätsklinikum Freiburg Uridina y análogos de uridina para el uso en el tratamiento de la enfermedad pulmonar obstructiva crónica
WO2015106255A1 (en) 2014-01-13 2015-07-16 City Of Hope Multivalent oligonucleotide assemblies
EP3182980B1 (en) * 2014-08-19 2020-10-14 Wellstat Therapeutics Corporation Treatment of glycosylation deficiency diseases
FR3027804A1 (fr) 2014-10-31 2016-05-06 Centre Nat Rech Scient Utilisation d'un inhibiteur de transcriptase inverse dans la prevention et le traitement des maladies degeneratives
US10675293B2 (en) 2015-05-29 2020-06-09 The Board Of Trustees Of The Leland Stanford Junior University Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes
IL289747B2 (en) 2015-06-05 2025-10-01 Fundacio Hospital Univ Vall Dhebron Institut De Recerca Combination of deoxyribonucleosides for the treatment of mitochondrial DNA depletion syndrome and/or deletion syndrome
LT3505174T (lt) * 2015-06-17 2020-09-10 The Trustees Of Columbia University In The City Of New York Deoksinukleozidų terapija, skirta gydyti ligas, kurias sukelia nesubalansuoti nukleotidų kiekiai, įskaitant mitochondrinės dnr išsekimo sindromus
CA3008849A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
KR101981843B1 (ko) 2016-09-13 2019-05-23 울산대학교 산학협력단 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 미토콘드리아 기능 개선용 조성물
AU2019242628A1 (en) 2018-03-26 2020-09-24 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
JP2022546611A (ja) * 2019-09-05 2022-11-04 ミトレインボー セラピューティクス，インコーポレーテッド ミトコンドリアｄｎａ枯渇障害の処置
US20210315880A1 (en) 2020-03-20 2021-10-14 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
KR102290596B1 (ko) 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도
US20230357304A1 (en) * 2020-09-14 2023-11-09 Wellstat Therapeutics Corporation 2′,3′-Diacetyluridine Substituted With Acetoacetyl at the 5′ Position
EP3970713A1 (en) 2020-09-16 2022-03-23 GV Squared S.r.l. Pharmaceutical composition comprising uridine and pyruvate for regulating the profileration, activity and survival of immune cells
CN113116900B (zh) * 2021-04-14 2022-07-08 兰州大学 一类核苷类似物在制备预防和/或治疗脑血管疾病药物中的应用
BE1030026B1 (fr) * 2022-06-14 2023-07-07 Dendrogenix Composés dérivés de stérols et composition pharmaceutique les comprenant pour leur utilisation dans la prévention, l’amélioration et/ou le traitement d’une pathologie liée à un déficit mitochondrial

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
JPS5356690A (en) * 1976-09-30 1978-05-23 Rikagaku Kenkyusho Purin compund sugar derivatives and their preparation
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US6348451B1 (en) 1987-10-28 2002-02-19 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
HK1005740A1 (en) * 1987-10-28 1999-01-22 Wellstat Therapeutics Corporation Acylated uridine and cytidine and uses thereof
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US6743782B1 (en) 1987-10-28 2004-06-01 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US6060459A (en) 1987-10-28 2000-05-09 Pro-Neuron, Inc. Enhancing blood cell count with oxypurine nucleosides
US6329350B1 (en) 1987-10-28 2001-12-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
DE3855513T2 (de) 1987-10-28 1997-01-09 Pro Neuron Inc Acyl deoxyribonukleosid-derivate und deren verwendungen
US5691320A (en) * 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
DE3843241A1 (de) * 1988-12-22 1990-06-28 Skrezek Christian Nephroprotektive infusionsloesung
IT1241984B (it) 1990-06-13 1994-02-02 Polifarma Spa Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
WO1993024650A1 (en) * 1992-05-28 1993-12-09 Monash University Therapeutic compositions
US5567689A (en) 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5852000A (en) 1993-08-25 1998-12-22 Otsuka Pharmaceutical Factory, Inc. Cardiac rehabilitation agent
EP0751951A4 (en) * 1994-03-30 2000-05-03 Mitokor DIAGNOSIS, THERAPY AND CELL AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH MITOCHONDRIAL DEFECTS
JP3808121B2 (ja) * 1995-01-09 2006-08-09 日本メジフィジックス株式会社 低酸素症またはミトコンドリア機能障害診断剤
US5962459A (en) 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
JPH10273469A (ja) * 1997-02-03 1998-10-13 Takeda Chem Ind Ltd ２環性キノン誘導体、製造法および剤
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
ES2298130T3 (es) 1999-02-23 2008-05-16 The Regents Of The University Of California Uso de triacetiluridina para el tratamiento de trastornos mitocondriales.

Also Published As

Publication number Publication date
CN100379426C (zh) 2008-04-09
IL180528A0 (en) 2007-06-03
IL144964A (en) 2013-11-28
AU3243400A (en) 2000-09-14
AU2004235661A1 (en) 2005-01-27
DE60037578D1 (de) 2008-02-07
KR20070085864A (ko) 2007-08-27
CN1191835C (zh) 2005-03-09
KR20020031331A (ko) 2002-05-01
EP1808177A2 (en) 2007-07-18
DK1171137T3 (da) 2008-03-31
KR100758712B1 (ko) 2007-09-14
CN1341024A (zh) 2002-03-20
AU776437B2 (en) 2004-09-09
ATE381935T1 (de) 2008-01-15
PT1171137E (pt) 2008-03-17
JP2002537340A (ja) 2002-11-05
JP4776780B2 (ja) 2011-09-21
DE60037578T2 (de) 2009-01-08
HU230191B1 (hu) 2015-09-28
US8748408B2 (en) 2014-06-10
RU2001125913A (ru) 2005-02-20
ZA200107727B (en) 2007-10-31
KR100879559B1 (ko) 2009-01-22
RU2394580C2 (ru) 2010-07-20
EP1808177A3 (en) 2010-07-28
NZ513926A (en) 2001-09-28
US7638501B1 (en) 2009-12-29
CN1626107A (zh) 2005-06-15
WO2000050043A1 (en) 2000-08-31
IL144964A0 (en) 2002-06-30
EP1171137B1 (en) 2007-12-26
US20100098678A1 (en) 2010-04-22
RU2268732C2 (ru) 2006-01-27
EP1171137A4 (en) 2004-04-07
EP1171137A1 (en) 2002-01-16
IL180528A (en) 2013-11-28
HUP0400914A2 (hu) 2004-08-30
HUP0400914A3 (en) 2007-05-29
MXPA01008549A (es) 2003-06-06
CA2362925C (en) 2011-04-12
EP1808177B1 (en) 2018-08-08
BR0008447A (pt) 2002-01-15
CA2362925A1 (en) 2000-08-31
RU2005121711A (ru) 2007-01-20

Similar Documents

Publication Publication Date Title
ES2298130T3 (es) Uso de triacetiluridina para el tratamiento de trastornos mitocondriales.
CA3056072C (en) Methods of treating feline coronavirus infections
ES2748556T3 (es) Terapia de desoxinucleósidos para enfermedades causadas por grupos de nucleótidos desequilibrados incluyendo síndromes de agotamiento de ADN mitocondrial
ES2399846T3 (es) Inhibidores de MPO para el tratamiento de la enfermedad de Huntington y la atrofia multisistémica
WO1997035591A2 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
JP2025172733A (ja) ミトコンドリア病の治療
US20040224920A1 (en) Methods of treatment of mitochondrial disorders
JP2023546924A (ja) 神経系障害を処置するための抗プリン作動性組成物の投与
JP5362747B2 (ja) アルツハイマー病の治療用医薬品の調製のためのｓ−アデノシルメチオニン（ｓａｍ）およびスーパーオキシドジスムターゼ（ｓｏｄ）の使用
US11583561B2 (en) Composition for preventing, treating, or alleviating viral infection diseases or respiratory diseases comprising vesicle derived from Lactobacillus paracasei
ES2361185T3 (es) Composición farmacéutica basada en inhibidor de la transcriptasa inversa y meldonio.
JP2001518899A (ja) 他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
KR20010075202A (ko) 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
CN119816299A (zh) 尿苷三乙酸酯无定形制剂及其用途